Literature DB >> 1598872

Myocardial adenine nucleotide concentrations and myocardial norepinephrine content in patients with heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.

V Regitz1, E Fleck.   

Abstract

It has been suggested that chronically reduced myocardial adenosine triphosphate (ATP) content causes contractile dysfunction in dilated cardiomyopathy. Because total adenine nucleotides (ATP, adenosine diphosphate and monophosphate) may reflect chronic changes in energy metabolism better than may ATP alone, myocardial ATP, and adenosine diphosphate and monophosphate were determined in endomyocardial biopsy specimens from 19 patients with dilated cardiomyopathy, and decreased left (30 +/- 2%) and right (34 +/- 3%) ventricular ejection fractions, and from 11 patients with ischemic cardiomyopathy (left ventricular ejection fraction 38 +/- 3%), and compared with those from 28 normal control subjects (ejection fraction greater than 55%) to assess myocardial energy metabolism in heart failure. Myocardial norepinephrine was measured simultaneously in the same biopsy specimens to assess if the myocardium studied for adenine nucleotide content was metabolically altered. Myocardial total adenine nucleotides as well as ATP levels in 19 patients with dilated cardiomyopathy (39 +/- 3 and 23 +/- 3 nmol/mg of noncollagen protein, respectively) were unchanged in comparison with those of control subjects (37 +/- 4 and 23 +/- 3, respectively); patients with ischemic cardiomyopathy were not significantly different (30 +/- 3 and 19 +/- 3, respectively). Myocardial norepinephrine in the same biopsy specimens from patients with dilated (5.8 +/- 1.1 pg/micrograms of noncollagen protein) or ischemic (5.7 +/- 1.3) cardiomyopathy was significantly decreased compared with that of normal control subjects (12 +/- 1.1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1598872     DOI: 10.1016/0002-9149(92)90706-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Absolute quantification of high energy phosphate metabolites in normal, hypertrophied and failing human myocardium.

Authors:  S Neubauer; M Beer; W Landschütz; J Sandstede; T Seyfarth; C Lipke; H Köstler; W Pabst TKenn; M Meininger; M von Kienlin; M Horn; K Harre; D Hahn
Journal:  MAGMA       Date:  2000-11       Impact factor: 2.310

2.  Human myocardial ATP content and in vivo contractile function.

Authors:  R C Starling; D F Hammer; R A Altschuld
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

Review 3.  Is contractility depressed in the failing human heart?

Authors:  J K Gwathmey; R Liao; P A Helm; G Thaiyananthan; R J Hajjar
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

Review 4.  Failing energetics in failing hearts.

Authors:  P P Dzeja; M M Redfield; J C Burnett; A Terzic
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 3.955

Review 5.  Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.

Authors:  David A Brown; Justin B Perry; Mitchell E Allen; Hani N Sabbah; Brian L Stauffer; Saame Raza Shaikh; John G F Cleland; Wilson S Colucci; Javed Butler; Adriaan A Voors; Stefan D Anker; Bertram Pitt; Burkert Pieske; Gerasimos Filippatos; Stephen J Greene; Mihai Gheorghiade
Journal:  Nat Rev Cardiol       Date:  2016-12-22       Impact factor: 32.419

6.  High-resolution respirometry in human endomyocardial biopsies shows reduced ventricular oxidative capacity related to heart failure.

Authors:  Daniel Scheiber; Tomas Jelenik; Elric Zweck; Patrick Horn; Heinz-Peter Schultheiss; Dirk Lassner; Udo Boeken; Diyar Saeed; Malte Kelm; Michael Roden; Ralf Westenfeld; Julia Szendroedi
Journal:  Exp Mol Med       Date:  2019-02-14       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.